Paul Hergenrother: Finding New Targets by Way of Novel Pathways
While there are thousands of drugs on the market for human diseases, they only hit in the neighborhood of 200 targets, says Paul Hergenrother, professor of chemistry and a member of the Cellular Decision Making in Cancer (CDMC) Theme at the IGB. Many drugs aim at the same target and are either minor improvements or work in a different way. And, while there is some rationale for developing new drugs for old targets, Hergenrother has an entirely different goal.